Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:43:00.554Z.
Calculation as of: 2026-10-06T19:43:00.554Z.
Quote observation: 2026-10-06T19:40:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$632.95M
Price/OCF Ratio
18.95
TTM Avg
42.15
3Y Avg
42.15
5Y Avg
29.81
Market Cap
$658.16M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$658.58M
Price/OCF Ratio
2007.86
TTM Avg
1890.32
3Y Avg
1890.32
5Y Avg
1890.32
Market Cap
$611.75M
Price/OCF Ratio
N/A
TTM Avg
3847.94
3Y Avg
3847.94
5Y Avg
3847.94
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $637.85M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $632.95M | 18.95 | 42.15 | 42.15 | 29.81 |
| Aura Biosciences, Inc. (AURA)vs › | $632.51M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $621.21M | N/A | 72.20 | 236.60 | 236.60 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $620.13M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $658.16M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $658.58M | 2007.86 | 1890.32 | 1890.32 | 1890.32 |
| Helus Pharma Inc. (HELP)vs › | $660.66M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.75M | N/A | 3847.94 | 3847.94 | 3847.94 |
| Annexon, Inc. (ANNX)vs › | $664.38M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
